Align Technology stock fell 1.10 percent before October 28 results
Align Technology's stock dropped 1.10% on October 2, 2026, ahead of its Q3 2026 earnings report scheduled for October 28. The company's Q2 results showed clear aligner revenue growth but a decline in systems and services. Analysts maintain a "Moderate Buy" consensus with a target price significantly above the current stock price.
Align Technology stock falls 1.1 percent ahead of October 28 results
Align Technology's stock fell 1.1% to USD 143.74 on October 2, 2026, ahead of its Q3 2026 earnings report scheduled for October 28. The upcoming report will be closely watched due to a mixed Q2 performance, where Clear Aligner revenue grew while Imaging Systems and CAD/CAM Services revenue declined. Analysts have a "Moderate Buy" consensus with an average 12-month price target of USD 206.36, indicating significant upside potential from its current trading price.
Is Align Technology (ALGN) Undervalued As Its October 28 Earnings Date Nears?
Align Technology (ALGN) is set to release its Q3 2026 earnings on October 28, with its share price currently at US$145.35, down significantly over the past month and quarter. Despite a current undervaluation narrative suggesting a fair value of $206.36, the company faces risks from soft North American Invisalign demand and scanner pricing pressure. Investors are advised to consider both potential rewards and risks, while also exploring other investment opportunities.
Align Technology sets October 28 results. Align Technology stock is 27.49 percent below high
Align Technology has set October 28, 2026, as the date for its third-quarter 2026 results. The company's stock is currently trading 27.49 percent below its 52-week high. Second-quarter revenue increased 4.30 percent year over year, with strong growth in clear aligners but a decline in imaging systems and CAD/CAM services revenue.
Align Technology to Report Q3 2026 Financial Results October 28
Align Technology, Inc. announced it will release its third-quarter 2026 financial results on Wednesday, October 28, 2026, after the close of market. The results will be made public at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET to discuss the financial outcomes. The company is a leading global medical device company known for its Invisalign System, iTero intraoral scanners, and exocad CAD/CAM software.
Pulmonx Corp (LUNG-Q) Stock Price and News
This article provides current stock information for Pulmonx Corp (LUNG-Q), including its NASDAQ ticker, real-time price updates, and recent trading data. It also includes a news feed with analyst ratings, earnings call transcripts, and corporate announcements related to the company. Pulmonx Corporation is described as a medical technology company specializing in minimally invasive devices for chronic obstructive pulmonary diseases, based in Redwood City, California.
Align Technology to Announce Third Quarter 2026 Results on October 28, 2026
Align Technology (Nasdaq: ALGN) announced it will report its third quarter 2026 financial results on Wednesday, October 28, 2026, after market close. The company will release results at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET, accessible via its Investor Relations website. Align Technology is a global medical device company known for its Invisalign System, iTero intraoral scanners, and exocad CAD/CAM software.
Dental Equipment & Technology Stocks Q2 Earnings Review: Envista (NYSE:NVST) Shines
Envista (NYSE:NVST) led the dental equipment and technology sector in Q2 earnings, reporting a 7.1% year-on-year revenue increase to $730.5 million, exceeding analysts' expectations. Despite strong financial performance from several companies, the sector's stock prices generally declined post-earnings, with Envista down 18.2% and Align Technology (NASDAQ:ALGN) showing the weakest performance against estimates. The article also touches upon market uncertainties, from AI's impact to geopolitical tensions, influencing investor sentiment.
Align Technology Launches Campaign to Educate Adults on Tooth Movement
Align Technology has launched the "SHIFT Happens" campaign to educate adult patients about lifelong tooth movement and the benefits of Invisalign clear aligner treatment. The campaign provides resources to Invisalign-trained doctors to facilitate discussions on age-related dental shifts, aiming to reach the estimated 200 million US adults who could benefit from orthodontic treatment. This initiative focuses on the natural process of teeth shifting with age and offers customizable marketing tools for providers.
Align Technology Launches "SHIFT Happens" U.S. Campaign to Educate Adults About Lifelong Tooth Movement
Align Technology has launched a new U.S. campaign called "SHIFT Happens" to educate adults about the natural phenomenon of lifelong tooth movement. The campaign aims to connect Invisalign-trained doctors with consumers to explain how teeth shift over time and the benefits of Invisalign treatment in addressing these changes. It emphasizes that over 200 million U.S. adults could benefit from orthodontic treatment, and the campaign provides resources for doctors to engage with their communities.
Align Technology Launches “SHIFT Happens” U.S. Campaign to Educate Adults About Lifelong Tooth Movement
Align Technology has launched a new U.S. consumer campaign called “SHIFT Happens” to educate adults about lifelong tooth movement and the benefits of Invisalign treatment. The campaign highlights that teeth naturally shift over time, which can lead to crowding and other oral health issues. It aims to empower Invisalign-trained doctors with resources to connect with and inform potential patients about treatment options.
Align Technology Launches “SHIFT Happens” U.S. Campaign to Educate Adults About Lifelong Tooth Movement
Align Technology (Nasdaq: ALGN) has launched "SHIFT Happens," a new U.S. consumer campaign aimed at educating adults about lifelong tooth movement and the benefits of Invisalign treatment. The campaign provides resources and co-marketing opportunities for Invisalign-trained doctors to connect with and educate potential patients in their communities about how teeth can shift over time due to natural aging processes. This initiative seeks to address the large market of adults who could benefit from orthodontic treatment but are not currently receiving it.
Align Technology Launches “SHIFT Happens” U.S. Campaign to Educate Adults About Lifelong Tooth Movement
Align Technology has launched a new U.S. campaign called "SHIFT Happens" to educate adult consumers about the natural phenomenon of lifelong tooth movement and the benefits of Invisalign treatment. The campaign provides Invisalign-trained doctors with resources and opportunities to connect with potential patients and explain how Invisalign can address crowding, spacing, and misalignment that occur as teeth shift over time. This initiative aims to engage the estimated 200 million U.S. adults who could benefit from orthodontic treatment.
Align Technology (ALGN) Faces A Valuation Test As Its Growth Narrative Holds Up
Align Technology (ALGN) is currently trading at US$146.78, which is a significant discount to the analyst-estimated fair value of $209, implying it is 30% undervalued. The company's growth is driven by the expanding clinical indications for Invisalign and increasing adoption by general practitioner dentists, although regulatory probes and competition pose risks. Investors are advised to consider the mixed messages on valuation and recent returns and conduct their own analysis.
Align Technology (ALGN) Faces A Valuation Test As Its Growth Narrative Holds Up
Align Technology (ALGN) is experiencing a valuation test, with its shares trading at US$146.78. Despite mixed short-term returns, analysts peg its fair value at around $209, suggesting it is significantly undervalued. The company's expansion into new clinical indications for Invisalign and increasing adoption by general practitioners are seen as drivers for long-term revenue and earnings growth, though regulatory probes and competition pose potential risks.
Q2 Rundown: Dentsply Sirona (NASDAQ:XRAY) Vs Other Dental Equipment & Technology Stocks
This article analyzes the Q2 performance of several dental equipment and technology stocks, highlighting Dentsply Sirona (XRAY), Envista (NVST), Align Technology (ALGN), and Henry Schein (HSIC). It details their revenue growth, performance against analyst estimates, and stock price reactions, noting that the sector experienced strong Q2 revenues but subsequent stock price declines. The piece also touches on broader market shifts, including concerns over AI and geopolitics impacting investor focus.
RALGN to CAD: Align Technology, Inc. rStock Price in Canadian Dollar
This article provides the current conversion rate of Align Technology, Inc. rStock (RALGN) to Canadian Dollar (CAD), noting its price at CA$206.88. It details how to buy RALGN with CAD through crypto exchanges, outlining steps from identifying an exchange to completing a transaction. The article also includes historical price data, statistics, and frequently asked questions regarding RALGN to CAD conversions.
Align Technology stock falls 1.72 percent on Nasdaq
Align Technology's stock fell 1.72 percent on Nasdaq, closing at USD 145.62 on September 24, 2026. This drop occurred despite the company reporting Q2 revenue of USD 1,056.2 million, up 4.3 percent year over year, with Q3 revenue guidance set between USD 1.00 billion and USD 1.02 billion. Analysts maintain a "Moderate Buy" consensus with a 12-month price target significantly above the current market price.
Align Technology Inc. stock underperforms Thursday when compared to competitors
Align Technology Inc. (ALGN) stock declined by 1.72% on Thursday, closing at $145.63. This underperformance occurred on a day when the broader market also saw losses, with the S&P 500 Index falling 0.02% and the Dow Jones Industrial Average falling 0.31%. This marks the second consecutive day of losses for Align Technology Inc. shares.
Align Technology stock slips 3.34 percent ahead of the open
Align Technology's stock fell 3.34 percent ahead of market open on September 24, 2026, closing at USD 148.17 on September 23, 2026. This decline was larger than the Nasdaq Composite's 1.13 percent drop. The article also notes upcoming U.S. economic data releases for September 24, 2026, including jobless claims, building permits, and new home sales.
IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history
This article provides a comprehensive overview of IDEXX Laboratories, Inc. (IDXX) stock, including its current price, historical data, financial performance, and analyst insights. It details the company's operations across companion animal, water quality, and livestock segments, highlighting its diverse product and service offerings in diagnostics and research. The report also includes key financial metrics, performance comparisons against the S&P 500, and analysts' price targets.
Align Technology Inc. stock underperforms Wednesday when compared to competitors
Align Technology Inc. (ALGN) shares dropped 3.34% on Wednesday, closing at $148.17. This underperformance occurred during a negative trading session for the broader market, with both the S&P 500 and Dow Jones Industrial Average also declining. The stock is now 26.08% below its 52-week high.
Intuitive Surgical, Inc. (ISRG) Options Chain - Yahoo Finance
This article provides the options chain for Intuitive Surgical, Inc. (ISRG) on Yahoo Finance. It indicates that there are currently no calls or puts available, with options data delayed by 15 minutes. The page also displays current stock information for ISRG, showing a price of 396.65 with a -1.35% change as of 1:49:36 p.m. EDT.
Align Technology stock gains 4.36 percent before October results
Align Technology's stock rose 4.36% to USD 153.29 on September 22, 2026, ahead of its next quarterly report. The company reported Q2 2026 revenue of USD 1.06 billion and EPS of USD 2.64, surpassing analyst estimates. Align Technology is scheduled to release its Q3 2026 results on October 28, 2026.
Align Technology stock falls as quarterly growth stays modest
Align Technology's stock fell by 0.49% to USD 146.88 on September 21, 2026, despite reporting Q2 revenue of USD 1.06 billion and an EPS of USD 2.64, which beat analyst estimates by USD 0.02. The company's profit margin stood at 10.25%, and revenue increased 4.3% year-over-year. The stock remains significantly below its 52-week high of USD 200.44, with its next earnings report scheduled for October 28, 2026.
Align Technology Inc. stock outperforms competitors on strong trading day
Align Technology Inc. (ALGN) saw its stock advance by 4.36% to $153.29 on Tuesday, outperforming the broader market which saw the S&P 500 remain mostly unchanged and the Dow Jones Industrial Average fall. This rise broke a three-day losing streak for the company.
Weekly Recap: Guidance reiterated and Invisalign consumer headwinds
Align Technology (ALGN) maintained its full-year guidance despite consumer headwinds causing some patients to delay Invisalign treatment. The company saw a 7% rise in H1 case volume, with H2 growth projected at 5-6%, driven by strength in DSOs, North American retail, and potential market share gains in China. Demand for Invisalign persists, and growth opportunities remain in both U.S. and international markets.
Align Technology Adds iRhythm CEO Quentin Blackford to Board
Align Technology has appointed Quentin Blackford, CEO of iRhythm Technologies, to its board of directors, effective August 31, 2026. This addition brings significant medical technology and digital healthcare expertise to Align's board as long-serving director Andrea Saia prepares to retire. Blackford's experience at iRhythm, Dexcom, NuVasive, and Zimmer Holdings is expected to contribute to Align's oversight and strategic growth.
How Investors May Respond To Align Technology (ALGN) Lower Revenue Guidance
Align Technology recently presented at the 2026 Global Healthcare Conference, revealing quarterly earnings that exceeded expectations but also lowered Q3 revenue guidance. This dual message highlights ongoing challenges from inflation and delayed elective dental treatments affecting demand for Align's products. The article suggests that investors need to balance short-term caution with a broader perspective on oral care, as the company's near-term performance hinges on a recovery in patient traffic and case starts.
Illumina Names Chief Commercial Officer and Chief Legal Officer
Illumina Inc. has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer. These new hires bring extensive leadership experience from the life sciences, diagnostics, and medical technology sectors, aiming to strengthen Illumina's executive team and drive continued growth and customer service.
Align Technology Stock: Is ALGN Underperforming the Healthcare Sector?
Align Technology (ALGN), known for its Invisalign system, has seen its stock underperform the healthcare sector despite its strong market position and high profitability. The company's recent weakness is attributed to a slow recovery in the dental market, with patients delaying elective procedures due to inflation and economic uncertainty. Although Q2 2026 results exceeded estimates, a lower Q3 revenue guidance further impacted the stock, leading analysts to maintain a "Moderate Buy" rating with a projected 38% upside.
Align Technology Sees Invisalign Growth Runway Despite Consumer Headwinds
Align Technology's CFO, John Morici, stated that the company sees significant growth potential for its Invisalign clear aligners, despite challenges from inflation and patient reluctance. Morici emphasized the opportunity to convert traditional wires-and-brackets cases to clear aligners in both U.S. and international markets. The company is focusing on product and financing options to support conversion, international expansion, and strategic approaches to volume-based procurement in China.
Piper Sandler Maintains Align Technology(ALGN.US) With Buy Rating, Maintains Target Price $235
Piper Sandler has reiterated its Buy rating for Align Technology (ALGN.US) and maintained its price target at $235. This indicates a continued positive outlook from the analyst firm on the company's stock.
Align Technology (ALGN) Following Invisalign Expansion, Fair Value Still Sits Higher
Align Technology (ALGN) is heading into its 2026 Global Healthcare Conference with its stock currently trading at $147.0, a significant drop from its estimated fair value of $209.07, suggesting it is 30% undervalued. This valuation is based on the continued expansion of Invisalign, increasing adoption by general practitioner dentists, and anticipated double-digit earnings growth, despite recent short-term share price pressure and an EU antitrust investigation. Investors are encouraged to consider these factors alongside potential risks to make informed decisions.
Align Technology stock gains as estimates hold at USD 11.31
Align Technology's stock showed gains as its 2026 earnings estimate remained steady at USD 11.31 per share. The company reported Q2 FY26 revenue of USD 1.06 billion, with a profit margin of 10.25 percent. Despite the positive estimates, the stock's after-hours price of USD 147.95 remained below the average analyst target of USD 208.60.
Transcript : Align Technology, Inc. Presents at 2026 Global Healthcare Conference, Sep-15-2026 03
Align Technology, Inc. presented at the 2026 Global Healthcare Conference on September 15, 2026, at 03:10 PM EDT. The event included a speech by Jeffrey Johnson, a senior medical technology analyst at Baird. The full transcript of the presentation is available to subscribers of MarketScreener.
Align Technology Inc. stock underperforms Monday when compared to competitors despite daily gains
Align Technology Inc. (ALGN) stock rose 1.45% on Monday, closing at $153.00, despite a generally negative day for the broader stock market. The S&P 500 Index fell 0.48% and the Dow Jones Industrial Average dropped 0.29%. This marked the second consecutive day of gains for Align Technology.
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
Cellectis has decided to abandon its donor-derived CAR-T cell therapy programs, citing a material change in the commercial and clinical landscape for treating blood cancers. The company will now focus its resources on "in vivo" gene editing medicines targeting cardiovascular disease, specifically two preclinical programs, HEAL-101 and HEAL-201. This strategic shift has led to a significant drop in Cellectis's share price, as it moves away from clinical-stage assets to therapies that have not yet been tested in humans.
Align Technology (ALGN) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed
Align Technology's stock has significantly declined over five years, yet current earnings multiples suggest it is undervalued. The company trades at a P/E ratio of 25.9x, close to its sector average, while its fair P/E is estimated at 30.0x, indicating a potential discount. Despite this, broader valuation metrics present a mixed picture, suggesting investor caution regarding future demand and profitability.
STAAR Surgical hires former CEO to lead commercial team
STAAR Surgical has appointed former CEO David Bailey as its new chief commercial officer. Bailey previously led STAAR from 2001 to 2008 and was instrumental in blocking Alcon's attempted takeover of the company last year. He plans to focus on growing sales in established markets and expanding into new patient populations globally.
Align Technology options: bullish $220 call dominates flow as ALGN stock slides
Despite Align Technology (ALGN) stock sliding over 3% intraday, a significant bullish options bet was placed on the Jan 15, 2027 $220 call, accounting for 82.8% of all ALGN options volume today. This large trade, nearly doubling existing open interest, indicates fresh positioning that anticipates a roughly 43% rally in the stock by early 2027. The unusual 13:1 call-to-put ratio, amidst falling 3-month implied volatility and rising out-of-the-money put skew, suggests a high-conviction directional bet against the current market sentiment.
Has Align Technology (ALGN) Fallen Far Enough To Look Undervalued?
Align Technology (ALGN) stock has seen a significant 78% decline over the past five years, leading to questions about its current valuation. While Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by about 49%, its P/E ratio is largely in line with its industry peers. The article concludes that despite indicators of undervaluation, investors must consider whether the company can sustain its cash generation and margins to close the intrinsic value gap, or if it presents a potential value trap.
What Does Align Technology (ALGN) Gain From Its Board Change?
Align Technology (ALGN) has appointed Quentin Blackford of iRhythm Technologies to its board of directors, while Andrea L. Saia is set to resign after more than a decade of service. This change introduces new operating and strategy experience aligned with Align Technology's focus on digital workflow investments and manufacturing expansion. The move is expected to support governance continuity and will be evaluated by how the company executes its digital and manufacturing programs through 2027.
Align Technology (ALGN) Could Be 24% Undervalued On Mixed Earnings Guidance
Align Technology (ALGN) is considered 24% undervalued despite recent mixed earnings guidance, which included meeting revenue, exceeding earnings forecasts, but also issuing softer future guidance. The stock has seen a 12% drop since its earnings release, contributing to a 9.26% decline over 30 days, though its one-year return remains positive. The undervaluation narrative suggests a fair value of $209.07 against its current $158.64, driven by expectations of expanding clinical indications for Invisalign and increased adoption by general practitioners.
Align Technology (ALGN) Could Be 24% Undervalued As Soft Guidance Hits Shares
Align Technology (ALGN) recently reported quarterly results with revenue matching expectations but softer guidance for the next quarter led to a 12.2% stock pullback. Despite this, the company is considered 23.5% undervalued with a fair value of $209.07 per share, driven by expanding clinical indications for Invisalign and increasing adoption by dentists. The article highlights both growth potential and risks, including an EU antitrust investigation and pressure from lower-priced products.
Q2 Earnings Outperformers: Align Technology (NASDAQ:ALGN) And The Rest Of The Dental Equipment & Technology Stocks
The article reviews the Q2 performance of several dental equipment and technology stocks, highlighting Align Technology (NASDAQ:ALGN) as the weakest performer against analyst estimates despite revenue growth, and Envista (NYSE:NVST) as the strongest with the fastest revenue growth. Dentsply Sirona (NASDAQ:XRAY) experienced revenue decline but beat EPS estimates, while Henry Schein (NASDAQ:HSIC) showed strong performance with significant beats on expectations. Overall, the sector saw mixed market reactions post-earnings, with most stocks declining despite many beating revenue estimates.
STAAR Surgical Company Announces Appointment of Ben Park as Chief Technology Officer
STAAR Surgical Company has announced the appointment of Ben Park, Ph.D., as its new Chief Technology Officer. Dr. Park, who joins STAAR's Executive Committee, previously served as Head of Emerging Technology at Align Technology Inc. He brings extensive experience in developing and launching health technology products globally, holding numerous patents and peer-reviewed publications.
Align Technology Inc. stock outperforms competitors on strong trading day
Align Technology Inc. (ALGN) saw its stock rise by 2.70% to $159.15 on a strong trading day, outpacing broader market indices like the S&P 500 and Dow Jones Industrial Average. Despite this gain, the company's stock remains 20.60% below its 52-week high.
Align Technology (ALGN) Stock May Trade At A Discount Following Its 78% Five Year Fall
Align Technology's stock has seen a significant 78.4% drop over the last five years, yet recent performance shows strong gains. Despite this, the stock trades at a P/E ratio of 26.6x, which is below its estimated fair P/E of 30.2x and industry averages, suggesting it may be undervalued. The company faces a debate between its platform growth potential and risks like competitive pressure and an ongoing EU antitrust case.
Align Tech adds Quentin Blackford to board
Align Technology has appointed Quentin Blackford, president and CEO of iRhythm Technologies, to its board of directors, expanding the board to eleven members. Blackford brings extensive experience in global healthcare and digital innovation. Concurrently, long-serving director Andrea L. Saia will retire, with the board size returning to ten members by September 23, 2026.
